IGF::OT::IGF ALZHEIMER'S DISEASE PRECLINICAL EFFICACY DATABASE (ALZPED)

IGF::OT::IGF 阿尔茨海默病临床前疗效数据库 (ALZPED)

• 批准号: 9162996
• 负责人: SANJAY PATEL
• 金额: $ 23.46万
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-12-22 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9162996
• 关键词: Alzheimer' s Disease; Animal Model; Biological Markers; Biological Models; Caenorhabditis elegans; Clinic; Clinical Trials; Conflict of Interest; Data; Data Analyses; Data Base Management; Databases; Diet; Disease; Dose; Drosophila genus; Drug Formulations; Foundations; Genetic; Glean; Housing; Industry; Intellectual Property; Intervention; Literature; Measures; Methods; Mining; Mus; National Institute on Aging; Neurosciences; Online Systems; Outcome Measure; Pharmaceutical Preparations; Pharmacology and Toxicology; Phase; Preclinical Testing; Property; Publication Bias; Publications; Rattus; Reproducibility; Research Design; Research Personnel; Route; Scientist; Services; Source; System; Testing; Therapeutic; Therapeutic Agents; Translations; clinical trials in animals; data management; data mining; design; preclinical efficacy; preclinical study; primary outcome; secondary outcome; therapeutic target; treatment duration

To mitigate this challenge and increase the translation of Alzheimer’s Disease (AD) therapies to the clinic the National Institute on Aging (NIA)/ Division of Neuroscience (DN) proposes to create a publically available data repository (Alzheimer’s Preclinical Efficacy Database or AlzPED) containing information relating to the preclinical testing of candidate therapeutic agents in AD animal models. More specifically, within the scope of this project the NIA/ DN proposes to develop and implement a web-based portal for housing, sharing and mining of data relating to the preclinical testing of therapeutic agents in AD animal models. We envision that the portal would house experimental details, designs and, analyses of both positive and negative data. The AlzPED database will be broadly available to scientists from academic centers, industry, disease-focused foundations and the lay public. To populate the database data will be gleaned from at least two sources; 1) the scientific literature; 2) directly from researchers. Data will be submitted through a curator and will include information on the animal models, conditions of housing and diet, study design, primary and secondary outcome measures, statistical plan, therapeutic agents (e.g., drugs, biologics), formulation, route of administration, dose and duration of treatment, data analyses and results. These features of the database should aid in establishing standardized methods and best practices, thus increasing reproducibility of studies and limiting publication bias against negative results.

为了缓解这一挑战并增加阿尔茨海默病（AD）治疗方法的临床转化，国家衰老研究所(NIA)/神经科学部门（DN）建议创建一个公开可用的数据库（阿尔茨海默病临床前疗效数据库或AlzPED），其中包含与阿尔茨海默病动物模型中候选治疗药物的临床前测试相关的信息。更具体地说，在这个项目的范围内，NIA/ DN建议开发和实施一个基于网络的门户网站，用于存储、共享和挖掘与阿尔茨海默病动物模型中治疗药物临床前测试相关的数据。我们设想门户网站将容纳实验细节、设计和正面和负面数据的分析。AlzPED数据库将广泛地提供给来自学术中心、工业界、关注疾病的基金会和普通公众的科学家。要填充数据库，将从至少两个来源收集数据；1)科学文献；2)直接来自研究人员。数据将通过管理员提交，包括有关动物模型、住房和饮食条件、研究设计、主要和次要结果测量、统计计划、治疗剂（如药物、生物制剂）、配方、给药途径、剂量和治疗持续时间、数据分析和结果的信息。数据库的这些特征应有助于建立标准化方法和最佳做法，从而提高研究的可重复性，并限制对负面结果的出版偏见。